Sangamo: Did It Work? (Part II)
(WorldNews Health)

Introduction: Sangamo (SGMO) has rapidly become one of the most popular companies among retail investors, endowed with the promise of heralding in a new era of in vivo gene editing and ripe with the potential for profound price movement. The company maintains its position as one of the most talked about companies on social media and has sparked a flurry of articles from authors on Seeking Alpha. Source: Publicly available tweets After the company released data in September 2018, a number of authors weighed in on the company´s prospects with predominately bullish sentiment. In-Depth Analysis Of SB-913 Early Clinical Readout For MPS II Sangamo (Part V): Assessing The Prospects Of SB-913...